J
Jane M. Andrews
Researcher at Royal Adelaide Hospital
Publications - 329
Citations - 14638
Jane M. Andrews is an academic researcher from Royal Adelaide Hospital. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 48, co-authored 298 publications receiving 12270 citations. Previous affiliations of Jane M. Andrews include St. Vincent's Health System & Health Science University.
Papers
More filters
Journal ArticleDOI
Pregnancy and IBD treatment: this challenging interplay from a patients' perspective.
Réme Mountifield,Réme Mountifield,Réme Mountifield,Ruth Prosser,Peter A. Bampton,Peter A. Bampton,Kate Muller,Jane M. Andrews,Jane M. Andrews,Jane M. Andrews +9 more
TL;DR: This large retrospective study sought patient who reported pregnancy outcomes and examined the relationship between major adverse outcomes, IBD activity and treatment, and subjective data regarding patients' perceptions about IBD management and pregnancy.
Journal ArticleDOI
Does Computerized Cognitive Behavioral Therapy Help People with Inflammatory Bowel Disease? A Randomized Controlled Trial.
TL;DR: This is a randomized controlled trial of a self-administered CCBT intervention for patients with IBD focused on improving HRQOL, and it is hypothesized that CCBT completers will have an improvedHRQOL relative to people not allocated to CCBT.
Journal ArticleDOI
Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.
A. Agarwal,Jane M. Andrews +1 more
TL;DR: Pyoderma gangrenosum in inflammatory bowel disease (IBD) is uncommon and therapeutically challenging and its treatment remains poorly characterised due to limited individual centre or practitioner experience.
Journal ArticleDOI
Feasibility of a Patient-Centered Deprescribing Process to Reduce Inappropriate Use of Proton Pump Inhibitors
Emily Reeve,Emily Reeve,Jane M. Andrews,Michael D. Wiese,Ivanka Hendrix,Michael S. Roberts,Sepehr Shakib +6 more
TL;DR: The patient-centered deprescribing process can safely reduce inappropriate PPI prescribing in a small proportion of people, and difficulties in accessing complete medical histories, time limitations, and minimal evidence to support effectiveness in certain indications were barriers to implementation of the process in clinical practice.
Journal ArticleDOI
Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
TL;DR: This data indicates that continuation of concurrent therapy with both 5‐aminosalicylic acid and mesalazine and an immunomodulator is necessary for the treatment of inflammatory bowel disease.